AGMB

Business Context and Reporting Period

Company: AgomAb Therapeutics NV (Ticker: AGMB)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: AgomAb is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for fibro-inflammatory diseases. The company's pipeline centers on organ-restricted small molecule inhibitors of the TGF-β pathway. Key assets include ontunisertib (AGMB-129) for Fibrostenosing Crohn's Disease (FSCD) and AGMB-447 for Idiopathic Pulmonary Fibrosis (IPF).
Recent Milestone: The company completed its Initial Public Offering (IPO) on February 9, 2026, listing on the Nasdaq Global Select Market. This event occurred after the reporting period but significantly impacts the company's capital structure and liquidity.

Key Financial Metrics

Note: The company has no revenue and incurs losses primarily from Research & Development (R&D) and General & Administrative (G&A) expenses. The increase in net loss for 2025 was driven by higher R&D spend and a €4.9 million loss from changes in the fair value of contingent consideration liabilities.

Material Changes vs. Prior Period

• R&D Expenses: Increased by €9.6 million (24%) to €48.9 million. This reflects clinical progression for ontunisertib (Phase 2a STENOVA trial) and AGMB-447 (Phase 1 trial).
• Contingent Consideration: A €4.9 million loss was recognized due to the revaluation of earn-out liabilities related to the acquisition of Agomab Spain. This was partially offset by a €3.0 million cash payment made for the first milestone tranche.
• Liquidity: Cash and cash equivalents decreased by approximately €85 million due to operating burn and investing activities (including a €30 million investment in money market funds and the €3 million milestone payment). However, total liquid assets remain robust at €116.5 million.
• Share-Based Compensation: Increased significantly due to the acceleration of vesting for Employee Stock Option Plans (ESOPs) in anticipation of the IPO.

Guidance, Outlook, and Risks

Outlook and Guidance

• Cash Runway: Management expects existing cash, cash equivalents, and cash investments (including net IPO proceeds of ~$188 million) to fund operations into the first half of 2029.
• Clinical Milestones:
  • Ontunisertib: Preparing to initiate a Phase 2b trial in the second half of 2026. Results from the 48-week open-label extension of the Phase 2a STENOVA trial are expected in H2 2026.
  • AGMB-447: Phase 1 data in IPF patients expected in H2 2026. Phase 2 proof-of-concept study initiation planned for H2 2026.

Material Risks and Contingencies

• Internal Controls: The company identified material weaknesses in internal control over financial reporting for 2024 and 2025, citing a lack of formal documented processes and insufficient segregation of duties. Remediation is underway, but effectiveness is not yet assured.
• Regulatory Uncertainty: No established endpoints exist for FSCD; the company is working with the FDA and STAR Consortium to validate endpoints (e.g., S-PRO, MRE). Failure to validate these could delay approval.
• Capital Needs: As a clinical-stage company with no revenue, the company requires substantial additional capital to complete development and commercialization. Failure to raise funds could force delays or termination of programs.
• PFIC Status: There is a significant risk the company may be classified as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes, which could have adverse tax consequences for U.S. holders.

Investor Verification Checklist

• Remediation of Internal Controls: Verify the timeline and progress of remediation for the identified material weaknesses in financial reporting.
• STENOVA Trial Data: Monitor the upcoming H2 2026 data release for the open-label extension to confirm the durability of the safety and efficacy signals observed in Part A.
• Endpoint Validation: Track regulatory feedback regarding the validation of novel endpoints (S-PRO, MRE) for FSCD, as this is critical for future Phase 3 design.
• Contingent Consideration Liability: Review future fair value adjustments to the earn-out liability, which can cause significant volatility in reported net loss.
• Capital Efficiency: Assess the burn rate relative to the projected runway into 2029, considering the timing of the Phase 2b and Phase 2 trials.